The Golden Dose on Mounjaro: finding the dose that works for you

Why the golden dose is a decision, not a destination on a chart

There is a common assumption that everyone's golden dose turns out to be the highest one. That's not how the evidence plays out. In the SURMOUNT-1 clinical trial, participants who completed 72 weeks at 10 mg and 15 mg both showed substantial average weight loss, yet plenty of people in real-world practice find that a mid-range dose delivers what they need without the GI disruption that sometimes accompanies the highest strengths. The right dose for you is the one where weight is still moving in the right direction and daily life remains normal. That balance looks different for every person, and our Mounjaro golden dose guide explores what finding that balance tends to look like in practice.

Mounjaro's licensed schedule runs from 2.5 mg up through 5, 7.5, 10, 12.5, and 15 mg. The first pen (the 2.5 mg starting dose) exists to settle your digestive system, not to produce significant weight loss in itself. Thinking of it as a therapeutic dose can lead to premature disappointment. Its job is adjustment. From there, titration is a collaborative process: your prescriber looks at how your body has responded over roughly the previous four weeks before recommending whether to stay or step up. At nume, no dose increase is issued without that clinical re-review, which is why repeat orders go back to a qualified prescriber rather than processing automatically. You can read more about the full titration process on our Mounjaro overview.

One practical note: some people feel pressure to push to the highest dose as quickly as possible. Slower titration (staying at a dose for longer than the minimum four weeks if side effects are still present) is a legitimate clinical strategy, not a failure. The prescriber is there to guide that call.

What the 5 mg dose reveals, and why it matters for golden-dose decisions

The 5 mg dose occupies an interesting position in the titration ladder. For some patients it turns out to be the golden dose: weight loss is consistent, nausea has settled, and there's no clinical reason to push further. For others it's a midpoint with more room to go. Neither outcome is wrong. The distinction matters because stepping up when you don't need to introduces tolerability risk for no additional benefit specific to you.

Nausea, loose stools, indigestion, and fatigue are the side effects most commonly reported early in treatment or after a step-up, according to the NHS medicines page for tirzepatide. Most settle within days to a couple of weeks. If they don't (or if they're severe enough to affect eating and hydration) staying at the current dose longer before increasing is the sensible path. A prescriber can help distinguish temporary adjustment from a sign that the current dose isn't well tolerated long-term.

People curious about what the 5 mg experience looks like in practice often find our page on the 5 mg golden dose useful as a reference point when having that conversation with their prescriber. Similarly, those who want detail on the very first pen can find it on our page covering the 2.5 mg starting dose.

How your prescriber decides whether your golden dose has arrived

In a clinical setting, three things broadly signal that a patient has found their working dose: weight is continuing to move at a meaningful rate; side effects are either absent or have settled to something tolerable; and the prescriber's review of the clinical picture supports staying put. NICE's appraisal of tirzepatide, TA1026, notes that if weight loss is below 5% after six months at the highest tolerated dose, continuing the treatment should be reviewed. That threshold is a useful reference point, it underscores that the goal of titration is meaningful response at the right dose, not simply reaching the top of the schedule.

At nume (that is, at our clinician-led pharmacy service) repeat orders are assessed by a GPhC-registered Independent Prescriber every time. Evidence of weight progress and tolerability is part of that review, so the question of whether your current dose is working isn't something you're left to answer alone. If you're at an early dose and wondering whether your golden dose might be lower than you expected, that's exactly the kind of thing to raise at your next prescriber review rather than second-guessing through a dose increase.

If you're considering starting Mounjaro and want to understand how this process begins, our page on preparing for your first dose covers what to expect in those initial weeks.

Cost, dose, and the realistic picture

There is a financial dimension to the golden-dose question that's worth acknowledging honestly. Higher doses cost more per pen, and for some people the golden dose being a mid-range strength rather than the maximum is practically as well as clinically welcome. Since Eli Lilly revised Mounjaro's UK list pricing in September 2025, private prices have ranged roughly £149–£375 per four-week pen depending on dose and provider, our page on the 2025 price increase has the full context. The point isn't to steer towards a cheaper dose; it's to be transparent that the golden dose concept has real-world financial relevance too, and that a genuinely optimised dose isn't always the highest one.

At nume, everything in our service is priced on one transparent basis: no separate consultation fee, no prescription charge, no delivery fee, and no subscription that auto-renews without clinical review. Current treatment pricing is visible on our treatment page. We're not the cheapest option on the market. That's a deliberate choice, clinical re-review at every repeat, identity verification, live weight checks, and seven-day aftercare don't come free, and for a prescription medicine, that infrastructure is the part that actually matters.